Nisa Investment Advisors LLC decreased its stake in shares of  Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 3.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 379,768 shares of the biopharmaceutical company’s stock after selling 15,192 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Gilead Sciences were worth $32,603,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Jacobs & Co. CA increased its holdings in shares of  Gilead Sciences by 0.5% during the 4th quarter. Jacobs & Co. CA now owns 26,986 shares of the biopharmaceutical company’s stock valued at $2,316,000 after purchasing an additional 127 shares in the last quarter.  Capital Advisors Ltd. LLC increased its holdings in  Gilead Sciences by 29.4% in the 3rd quarter. Capital Advisors Ltd. LLC now owns 607 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 138 shares in the last quarter.  Mastrapasqua Asset Management Inc. increased its holdings in  Gilead Sciences by 4.5% in the 3rd quarter. Mastrapasqua Asset Management Inc. now owns 3,494 shares of the biopharmaceutical company’s stock worth $216,000 after acquiring an additional 150 shares in the last quarter.  GHP Investment Advisors Inc. increased its holdings in  Gilead Sciences by 1.7% in the 3rd quarter. GHP Investment Advisors Inc. now owns 8,951 shares of the biopharmaceutical company’s stock worth $552,000 after acquiring an additional 153 shares in the last quarter.  Finally, JFS Wealth Advisors LLC increased its holdings in  Gilead Sciences by 68.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 400 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 162 shares in the last quarter. Institutional investors own  78.72% of the company’s stock.

Several brokerages recently commented on GILD. Morgan Stanley boosted their price target on shares of Gilead Sciences from $81.00 to $85.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 12th. Cowen boosted their price target on shares of Gilead Sciences from $90.00 to $95.00 in a report on Friday, February 10th. Barclays boosted their price target on shares of Gilead Sciences from $76.00 to $84.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 18th. Robert W. Baird boosted their price target on shares of Gilead Sciences from $69.00 to $80.00 in a report on Friday, February 3rd. Finally, StockNews.com assumed coverage on shares of Gilead Sciences in a report on Thursday, March 16th. They set a “strong-buy” rating for the company. Nine research analysts have rated the stock with a hold rating, eight have issued  a buy rating and one  has issued  a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $89.60.

In other Gilead Sciences news, insider Merdad Parsey sold 6,126 shares of the business’s stock in a transaction dated Monday, March 13th. The shares were sold at an average price of $78.99, for a total transaction of $483,892.74. Following the sale, the insider now directly owns 70,130 shares in the company, valued at $5,539,568.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own  0.21% of the company’s stock.

NASDAQ GILD opened at $83.72 on Wednesday. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.29 and a quick ratio of 1.15. The stock has a market capitalization of $104.55 billion, a P/E ratio of 22.95, a PEG ratio of 0.99 and a beta of 0.38. The firm’s 50-day moving average is $81.97 and its two-hundred day moving average is $81.17. Gilead Sciences, Inc. has a 12 month low of $57.17 and a 12 month high of $89.74.

Gilead Sciences (NASDAQ:GILD – Get Rating) last issued its quarterly earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.50 by $0.17. The company had revenue of $7.39 billion for the quarter, compared to analyst estimates of $6.63 billion. Gilead Sciences had a net margin of 16.83% and a return on equity of 44.46%. The business’s revenue for the quarter was up 2.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.69 earnings per share.  On average, sell-side analysts anticipate that  Gilead Sciences, Inc. will post 6.86 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 30th. Shareholders of record on Wednesday, March 15th were paid a dividend of $0.75 per share. The ex-dividend date of this dividend  was Tuesday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.73. This represents a $3.00 dividend on an annualized basis and a yield of 3.58%. Gilead Sciences’s dividend payout ratio  is 82.19%.

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating).

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.